MarketInOut Stock Screener Log In | Sign Up

Contineum Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/16/2026 10:54
Contineum Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization385.39 mln
Float31.77 mln
Earnings Date03/11/2027

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

21.43
Transformational upside

Relative Strength

83 / 100
Strongly outperforming

Debt / Equity

0.03
Debt-free

ROE

-26.97
Deeply negative

ROA

-25.63
Deeply negative

Business Description

Contineum Therapeutics is a San Diego-based clinical-stage company focused on developing small-molecule drugs to treat neurological, inflammatory, and immune system disorders. Its lead drug candidate, PIPE-791, targets a specific receptor in the brain and is being studied as a potential treatment for idiopathic pulmonary fibrosis and chronic pain. The company is also advancing PIPE-307, which works through a different receptor mechanism and is being evaluated for depression and relapsing-remitting multiple sclerosis. Formerly known as Pipeline Therapeutics, the company adopted its current name in November 2023 and has been operating since 2009.

Key Fundamentals

EPS-1.77
ROE-26.97
ROIC-548
ROA-25.63
EBITDA, mln-63.08
EV / EBITDA-1.54
EV / EBIT-1.53

Quote Details

Last 9.81
Change -0.05 (-0.51%)
Open 9.67
Volume 41,434
Turnover 406,468
Average Volume 606,362

Financial Ratios

Leverage Ratio1.05
Current Ratio31.11
Price / Book1.46
Price / Tangible Book1.46
Debt / Equity0.03

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price21.43
Short Ratio2.82
Short % of Float10.51

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.76% 32 / 100   
1 Month 38.56% 98 / 100   
2 Months -33.81% 21 / 100   
6 Months -23.72% 29 / 100   
1 Year -10% 38 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog